A Case of Thoracic SMARCA4-Deficient Undifferentiated
Tumor Successfully Treated with Combination Ipilimumab-Nivolumab
Yoshio Nakanoa*, Daisuke Sekinadaa,
Yusuke Kuzea, Norio Okamotoa, Iwao
Gohmaa, Yumiko Yasuharab
aDepartment of Respiratory Medicine, Sakai City
Medical Center, 1-1-1, Ebaraji-cho, West Ward, Sakai City, Osaka
Prefecture, 593-8304, Japan; Email:
bDepartment of Pathology, Sakai City Medical Center,
1-1-1, Ebaraji-cho, West Ward, Sakai City, Osaka Prefecture, 593-8304,
Japan
*Correspondence: Yoshio Nakano
Department of Respiratory Medicine Sakai City Medical Center, 1-1-1,
Ebaraji-cho, West Ward, Sakai City, Osaka Prefecture, 593-8304, Japan
Email:methylemon@yahoo.co.jp
Data availability statement: Data will be made available on
request.
Funding statement: This research did not receive any specific
grants from funding agencies in the public, commercial, or
not-for-profit sectors.
Conflict of interest statement: none.
Ethics approval statement: We adhere to the journal’s code of
ethics.
Patient consent statement: Written informed consent was
obtained from the patient for the publication of this case report.
Key Clinical Message The present case indicated that 1)
combination ipilimumab-nivolumab successfully showed clinical benefits
in the treatment of thoracic SMARCA4 -deficient undifferentiated
tumors ,and 2) the good tolerability of combination
ipilimumab-nivolumab.